{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:14:26Z","timestamp":1790640866349,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Fibroblast-like synoviocytes (FLS) have cancer cell-like characteristics, such as abnormal proliferation and resistance to apoptosis, and play a pathogenic role in rheumatoid arthritis (RA). Hyperproliferation of RA-FLS that can be triggered by the activation of interleukin-6\/signal transducer and activator of transcription 3 (IL-6\/STAT3) signaling destructs cartilage and bone in RA patients. Chrysoeriol is a flavone found in medicinal herbs such as Chrysanthemi Indici Flos (the dried capitulum of\n                      <jats:italic>Chrysanthemum indicum<\/jats:italic>\n                      L.). These herbs are commonly used in treating RA. Chrysoeriol has been shown to exert anti-inflammatory effects and inhibit STAT3 signaling in our previous studies. This study aimed to determine whether chrysoeriol inhibits hyperproliferation of RA-FLS, and whether inhibiting STAT3 signaling is one of the underlying mechanisms.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>IL-6\/soluble IL-6 receptor (IL-6\/sIL-6R)-stimulated RA-FLS were used to evaluate the effects of chrysoeriol. CCK-8 assay and crystal violet staining were used to examine cell proliferation. Annexin V-FITC\/PI double staining was used to detect cell apoptosis. Western blotting was employed to determine protein levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Chrysoeriol suppressed hyperproliferation of, and evoked apoptosis in, IL-6\/sIL-6R-stimulated RA-FLS. The apoptotic effect of chrysoeriol was verified by its ability to cleave caspase-3 and caspase-9. Mechanistic studies revealed that chrysoeriol inhibited activation\/phosphorylation of Janus kinase 2 (JAK2, Tyr1007\/1008) and STAT3 (Tyr705); decreased STAT3 nuclear level and down-regulated protein levels of Bcl-2 and Mcl-1 that are transcriptionally regulated by STAT3. Over-activation of STAT3 significantly diminished anti-proliferative effects of chrysoeriol in IL-6\/sIL-6R-stimulated RA-FLS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We for the first time demonstrated that chrysoeriol suppresses hyperproliferation of RA-FLS, and suppression of JAK2\/STAT3 signaling contributes to the underlying mechanisms. This study provides pharmacological and chemical justifications for the traditional use of chrysoeriol-containing herbs in treating RA, and provides a pharmacological basis for developing chrysoeriol into a novel anti-RA agent.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12906-022-03553-w","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T12:15:47Z","timestamp":1647432947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Chrysoeriol suppresses hyperproliferation of rheumatoid arthritis fibroblast-like synoviocytes and inhibits JAK2\/STAT3 signaling"],"prefix":"10.1186","volume":"22","author":[{"given":"Jia-Ying","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Qiong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Kui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Yao","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Le","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Xuan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy Sze-man","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lut Yi","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Ling","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,16]]},"reference":[{"issue":"9746","key":"3553_CR1","first-page":"1094","volume":"376","author":"L David","year":"2010","unstructured":"David L. Scott, Frederick Wolfe, Tom W J Huizinga. Rheumatoid arthritis Lancet. 2010;376(9746):1094\u2013108.","journal-title":"Rheumatoid arthritis Lancet"},{"key":"3553_CR2","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023\u201338.","journal-title":"Lancet"},{"key":"3553_CR3","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.clim.2004.12.009","volume":"115","author":"A Mor","year":"2005","unstructured":"Mor A, Abramson SB, Pillinger MH. The fibroblast-like synovial cell in rheumatoid arthritis: A key player in inflammation and joint destruction. Clin Immunol. 2005;115:118\u201328.","journal-title":"Clin Immunol"},{"key":"3553_CR4","first-page":"1650","volume":"32","author":"JG Walker","year":"2005","unstructured":"Walker JG, Smith MD. The Jak-STAT pathway in rheumatoid arthritis. J Rheumatol. 2005;32:1650\u20133.","journal-title":"J Rheumatol"},{"issue":"SUPPL. 2","key":"3553_CR5","first-page":"1","volume":"8","author":"C Gabay","year":"2006","unstructured":"Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther. 2006;8(SUPPL. 2):1\u20136.","journal-title":"Arthritis Res Ther"},{"issue":"10086","key":"3553_CR6","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/S0140-6736(17)31491-5","volume":"389","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet. 2017;389(10086):2338\u201348.","journal-title":"Lancet"},{"key":"3553_CR7","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60784-3","volume":"370","author":"JS Smolen","year":"2007","unstructured":"Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370:1861\u201374.","journal-title":"Lancet"},{"key":"3553_CR8","first-page":"417","volume":"56","author":"S Tarp","year":"2017","unstructured":"Tarp S, Furst DE, Boers M, Luta G, Bliddal H, Tarp U, et al. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: A systematic review meta-analysis. Rheumatology (Oxford). 2017;56:417\u201325.","journal-title":"Rheumatology (Oxford)"},{"issue":"SUPPL. 6","key":"3553_CR9","first-page":"37","volume":"51","author":"EM Ruderman","year":"2012","unstructured":"Ruderman EM. Overview of safety of non-biologic and biologic DMARDs. Rheumatology (Oxford). 2012;51(SUPPL. 6):37\u201343.","journal-title":"Rheumatology (Oxford)"},{"key":"3553_CR10","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/rheumatology\/kep096","volume":"48","author":"V Ravindran","year":"2009","unstructured":"Ravindran V, Rachapalli S, Choy EH. Safety of medium- to long-term glucocorticoid therapy in rheumatoid arthritis: A meta-analysis. Rheumatology (Oxford). 2009;48:807\u201311.","journal-title":"Rheumatology (Oxford)"},{"key":"3553_CR11","doi-asserted-by":"crossref","unstructured":"van Walsem A, Pandhi S, Nixon RM, Guyot P, Karabis A, Moore RA. Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: A network meta-analysis. Arthritis Res Ther. 2015;17.","DOI":"10.1186\/s13075-015-0554-0"},{"key":"3553_CR12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00011-012-0558-z","volume":"62","author":"R Jeyadevi","year":"2013","unstructured":"Jeyadevi R, Sivasudha T, Rameshkumar A, Kumar LD. Anti-arthritic activity of the Indian leafy vegetable Cardiospermum halicacabum in Wistar rats and UPLC-QTOF- MS\/MS identification of the putative active phenolic components. Inflamm Res. 2013;62:115\u201326.","journal-title":"Inflamm Res"},{"key":"3553_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/ptr.4689","volume":"27","author":"C Kim","year":"2013","unstructured":"Kim C, Kim MC, Kim SM, Nam D, Choi S H, Kim SH, et al. Chrysanthemum indicum L. extract induces apoptosis through suppression of constitutive STAT3 activation in human prostate cancer DU145 cells. Phytother Res. 2013;27:30\u20138.","journal-title":"Phytother Res"},{"key":"3553_CR14","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.biopha.2016.03.019","volume":"80","author":"DA Ananth","year":"2016","unstructured":"Ananth DA, Rameshkumar A, Jeyadevi R, Aseervatham GSB, Sripriya J, Bose PC, et al. Amelioratory effect of flavonoids rich Pergularia daemia extract against CFA induced arthritic rats. Biomed Pharmacother. 2016;80:244\u201352.","journal-title":"Biomed Pharmacother"},{"key":"3553_CR15","first-page":"2031","volume":"30","author":"XY Chen","year":"2011","unstructured":"Chen XY, Li J, Cheng WM, Jiang H, Zhang L, Hu R. Effect of total flavonoids from chrysanthemum indicum on ultrastructure and secretory function of synoviocytes in adjuvant Arthritis Rats. Lat Am J Pharm. 2011;30:2031\u20136.","journal-title":"Lat Am J Pharm"},{"key":"3553_CR16","doi-asserted-by":"crossref","unstructured":"Wu JY, Chen YJ, Bai L, Liu YX, Fu XQ, Zhu PL, et al. Chrysoeriol ameliorates TPA-induced acute skin inflammation in mice and inhibits NF-\u03baB and STAT3 pathways. Phytomedicine. 2020;68.","DOI":"10.1016\/j.phymed.2020.153173"},{"key":"3553_CR17","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.redox.2017.01.010","volume":"11","author":"AKW Tse","year":"2017","unstructured":"Tse AKW, Chen YJ, Fu XQ, Su T, Li T, Guo H, et al. Sensitization of melanoma cells to alkylating agent-induced DNA damage and cell death via orchestrating oxidative stress and IKK\u03b2 inhibition. Redox Biol. 2017;11:562\u201376.","journal-title":"Redox Biol"},{"key":"3553_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-79139-8","volume":"11","author":"YJ Chen","year":"2021","unstructured":"Chen YJ, Liu YX, Wu JY, Li CY, Tang MM, Bai L, et al. A two-herb formula inhibits hyperproliferation of rheumatoid arthritis fibroblast-like synoviocytes. Sci Rep. 2021;11:1\u20139.","journal-title":"Sci Rep"},{"key":"3553_CR19","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.4049\/jimmunol.171.6.3202","volume":"171","author":"MA Nowell","year":"2003","unstructured":"Nowell MA, Richards PJ, Horiuchi S, Yamamoto N, Rose-John S, Topley N, et al. Soluble IL-6 Receptor Governs IL-6 Activity in Experimental Arthritis: Blockade of Arthritis Severity by Soluble Glycoprotein 130. J Immunol. 2003;171:3202\u20139.","journal-title":"J Immunol"},{"key":"3553_CR20","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","volume":"112","author":"N Nishimoto","year":"2008","unstructured":"Nishimoto N, Terao K, Mima T, Nakahara H. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti\u2013IL-6 receptor antibody. Blood. 2008;112:3959\u201365.","journal-title":"Blood"},{"key":"3553_CR21","doi-asserted-by":"crossref","unstructured":"Hashizume M, Mihara M. The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis. Arthritis. 2011;2011:765624.","DOI":"10.1155\/2011\/765624"},{"key":"3553_CR22","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson DE, O\u2019Keefe RA, Grandis JR. Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15:234\u201348.","journal-title":"Nat Rev Clin Oncol"},{"key":"3553_CR23","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1016\/j.ejca.2005.08.016","volume":"41","author":"DR Hodge","year":"2005","unstructured":"Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer. 2005;41:2502\u201312.","journal-title":"Eur J Cancer"},{"key":"3553_CR24","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3390\/cancers6020897","volume":"6","author":"RL Carpenter","year":"2014","unstructured":"Carpenter RL, Lo HW. STAT3 target genes relevant to human cancers. Cancers. 2014;6:897\u2013925.","journal-title":"Cancers"},{"key":"3553_CR25","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.0105-2896.2009.00859.x","volume":"233","author":"B Bartok","year":"2010","unstructured":"Bartok B, Firestein GS. Fibroblast-like synoviocytes: Key effector cells in rheumatoid arthritis. Immunol Rev. 2010;233:233\u201355.","journal-title":"Immunol Rev"},{"key":"3553_CR26","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/j.1600-065X.2008.00648.x","volume":"223","author":"EH Noss","year":"2008","unstructured":"Noss EH, Brenner MB. The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis. Immunol Rev. 2008;223:252\u201370.","journal-title":"Immunol Rev"},{"key":"3553_CR27","doi-asserted-by":"publisher","first-page":"6610","DOI":"10.4049\/jimmunol.169.11.6610","volume":"169","author":"A Krause","year":"2002","unstructured":"Krause A, Scaletta N, Ji J-D, Ivashkiv LB. Rheumatoid Arthritis Synoviocyte Survival Is Dependent on Stat3. J Immunol. 2002;169:6610\u20136.","journal-title":"J Immunol"},{"key":"3553_CR28","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/j.0105-2896.2009.00854.x","volume":"233","author":"S Kyung Chang","year":"2010","unstructured":"Kyung Chang S, Gu Z, Brenner MB. Fibroblast-like synoviocytes in inflammatory arthritis pathology: The emerging role of cadherin-11. Immunol Rev. 2010;233:256\u201366.","journal-title":"Immunol Rev"},{"key":"3553_CR29","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1136\/ard.2003.013276","volume":"63","author":"P v Kasperkovitz","year":"2004","unstructured":"Kasperkovitz P v, Verbeet NL, Smeets TJ, van Rietschoten JGI, Kraan MC, et al. Activation of the STAT1 pathway in rheumatoid arthritis. Ann Rheum Di. 2004;63:233\u20139.","journal-title":"Ann Rheum Di"},{"key":"3553_CR30","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3390\/cells8060561","volume":"8","author":"Y Ikari","year":"2019","unstructured":"Ikari Y, Isozaki T, Tsubokura Y, Kasama T. Peficitinib Inhibits the Chemotactic Activity of Monocytes via Proinflammatory Cytokine Production in Rheumatoid Arthritis Fibroblast-Like Synoviocytes. Cells. 2019;8:561.","journal-title":"Cells"},{"key":"3553_CR31","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1093\/rheumatology\/ken363","volume":"47","author":"M Hashizume","year":"2008","unstructured":"Hashizume M, Hayakawa N, Mihara M. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-\u03b1 and IL-17. Rheumatology. 2008;47:1635\u201340.","journal-title":"Rheumatology"},{"key":"3553_CR32","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/1529-0131(200002)43:2<250::AID-ANR3>3.0.CO;2-P","volume":"43","author":"EM Gravallese","year":"2000","unstructured":"Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 2000;43:250\u20138.","journal-title":"Arthritis Rheum"},{"key":"3553_CR33","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nrrheum.2012.190","volume":"9","author":"N Bottini","year":"2013","unstructured":"Bottini N, Firestein GS. Duality of fibroblast-like synoviocytes in RA: Passive responders and imprinted aggressors. Nat Rev Rheumatol. 2013;9:24\u201333.","journal-title":"Nat Rev Rheumatol"}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-022-03553-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12906-022-03553-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-022-03553-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T12:16:36Z","timestamp":1647432996000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/s12906-022-03553-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,16]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3553"],"URL":"https:\/\/doi.org\/10.1186\/s12906-022-03553-w","relation":{},"ISSN":["2662-7671"],"issn-type":[{"value":"2662-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,16]]},"assertion":[{"value":"23 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"I declare that the authors have no competing interests as defined by BMC, or other interests that might be perceived to influence the results and\/or discussion reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}